I was just about say the same.I've been away but have been more than pleased with the recent strength of NMS at good volumes.Augers well for any capital raising via placement or issue at prices well in excess of $1.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%